Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $22
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $34 to $22.
Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $34 to $22.